Northwest Biotherapeutics Successfully Completes Acquisition of Advent BioServices, Aiming for Enhanced Operational Efficiency

Northwest Biotherapeutics Finalizes Acquisition of Advent BioServices

On October 24, 2025, Northwest Biotherapeutics, Inc. (OTCQB:NWBO), a pioneering biotechnology firm specializing in personalized immune therapies for solid tumor cancers, announced the successful closure of its acquisition of Advent BioServices Ltd. With this strategic move, Advent now operates as a wholly owned subsidiary of Northwest Biotherapeutics.

This acquisition is expected to lead to significant operational efficiencies and scaling up of the company’s capabilities. The leadership at Northwest Biotherapeutics believes that the integration of Advent's assets, technologies, and expertise will create a more comprehensive platform for innovation. The benefits expected from this acquisition include:

1. Integrated Technologies: The merger will combine the technologies, intellectual property, and skills from both Northwest Biotherapeutics and Advent, as well as Flaskworks, to foster novel approaches in cancer therapy.
2. Supply Chain and Facility Management: An overhaul in supply chain management and facility operations is anticipated, which will lead to more streamlined processes.
3. Resource Reallocation: The relocation of resources will occur from the GMP facility in London to the Sawston, UK facility, along with increased capacity development efforts in the US to augment manufacturing capabilities.
4. Enhanced Manufacturing: A major emphasis will be placed on improving the manufacturing capacity for DCVax products, ensuring a stronger production pipeline.
5. Clinical Site Interactions: Efforts to improve interactions with clinical sites will facilitate better distribution and collection of feedback regarding DCVax therapies.

Northwest Biotherapeutics will also benefit from Advent's valuable fixed assets, which include advanced cryostorage facilities and specialized equipment acquired by Advent over the past several years. Also included in the acquisition are essential intellectual properties that Advent developed during its operational history.

Interestingly, the acquisition involves no issuance of new shares or securities by Northwest Biotherapeutics. Instead, approximately 19 million securities that had been previously allocated to Advent as remuneration for contract services will revert back to Northwest Biotherapeutics as part of the deal. This includes 13.5 million shares and 5.5 million options.

The financial terms dictate that the purchase price will be settled in installments over the next two years, with the first payments kicking off 90 days post-acquisition closure. Furthermore, there is an option for accelerated payments contingent on regulatory approval of NWBio's flagship product, the DCVax®-L.

The financial outline of this acquisition includes a payment of £1.4 million, in addition to settling accounts payable due from NWBio to Advent concerning previous agreements regarding services rendered.

Linda Powers, CEO of Northwest Biotherapeutics, expressed her enthusiasm regarding the acquisition, stating, "We are excited to have completed the necessary conditions for closing the acquisition of Advent and to move forward into a position ripe for significant scale-up. This integration is set to enhance our capability to develop additional applications and next-generation iterations of our technologies, utilizing the combined expertise and extensive intellectual property portfolio we have amassed. This represents important advancement in solidifying our competitive position in the market."

About Northwest Biotherapeutics

Northwest Biotherapeutics aims to revolutionize cancer treatment through personalized immunotherapy solutions. The company focuses on producing DCVax® dendritic cell-based vaccines designed to treat various cancers with a methodology that seeks to avoid the toxicities commonly associated with conventional chemotherapy. Notably, their lead program, DCVax®-L, targets glioblastoma (GBM), a highly aggressive brain cancer, for which the company has completed extensive trials and is seeking commercial approval following an ongoing review process in the UK.

Recent developments also include the completion of a Phase I trial for DCVax®-Direct, aimed at inoperable solid tumors, further cementing NWBio's commitment to advancing innovative cancer care.